proved that CAR-T cell-derived exosomes can reduce the cytotoxicity of CAR-T therapies and have the ability to cross the blood-brain barrier and carry many cytotoxic molecules (FasL, Apo2L, perforin, etc.), which have demonstrated great efficacy as a gene-expression-regulating vector in tumor therapy (177). This evidence concerns the gene PRF1 and neoplasm.